Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment.
about
Efficacy and safety of sirolimus in lymphangioleiomyomatosis.Management of lymphangioleiomyomatosisClinical features, epidemiology, and therapy of lymphangioleiomyomatosisMulticenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decreaseUterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.Neurologic manifestations of tuberous sclerosis complex."Getting stuck with LAM": patients perspectives on living with lymphangioleiomyomatosis.Diffuse Cystic Lung Disease. Part I.Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response.Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis.Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosisSurvival and disease progression in UK patients with lymphangioleiomyomatosis.The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis.Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosisPrimary abdominal lymphangioleiomyomatosis: report of a case.Clinical experience of lymphangioleiomyomatosis in the UK.Lymphangioleiomyomatosis: a case-control study of perinatal and early life events.Sporadic lymphangioleiomyomatosis with bloody sputum as an initial symptom: A case report and review of the literatureLymphangioleiomyomatosis: a radiological diagnosis.Lymphangioleiomyomatosis: what do we know and what are we looking for?Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.Challenges in pulmonary fibrosis. 3: Cystic lung disease.Lymphangioleiomyomatosis - a wolf in sheep's clothing.Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM)St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosisLymphangioleiomyomatosis and tuberous sclerosis complex.The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.Lymphangioleiomyomatosis: New Treatment Perspectives.Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study.A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells.Evolution of pulmonary function after treatment with goserelin in patients with lymphangioleiomyomatosis.Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function.Summary for Clinicians: Lymphangioleiomyomatosis Diagnosis and Management Clinical Practice Guideline.Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis.Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients.
P2860
Q24610039-29B0B31D-2FA1-4B20-98CA-5A7CA27FBB36Q28084725-E885982D-CA5D-4097-98D2-E7217428BDC2Q28084975-FB0D829F-F241-45F4-B519-4281CE77E20EQ28476810-897A2B4D-321F-40EE-9E4F-81DFC71BB383Q30411083-FB57FB56-C94A-475A-B41B-5077DBB29047Q30680048-53C5D800-60C8-4C33-B50A-C2D80F3D97EAQ33685049-D36BBCB9-4C09-4876-9B3D-B6459E6EA1C0Q33722950-04F14FE9-3538-49F6-90F6-6B8CA3004961Q33823877-4D79FACB-F65C-45C8-9A58-D7070D3E3660Q34160683-60D1964D-E43E-44CA-89D8-F5CDD672B3A3Q34204852-32A262FF-7841-4635-9BF7-58C59B82F85DQ34343897-9879E7DC-D0B7-466F-8C3B-0A9A485FB72EQ34465125-569F19F9-AE45-465A-B477-8E03F4C4812DQ34536450-1A329900-83EC-4E29-9388-CD774CB67500Q34560457-EFB3859B-EFBE-4BA7-8BF5-CBED4E5DC832Q35164925-FB577478-6C6B-4BE2-A608-65DA3499D7FEQ35533560-9AA1F515-5C29-4168-AEA4-1E5DEFF0E6B3Q35535550-ECBF1FDE-D28A-4F3C-8B69-BB0CFCE82954Q35758056-7FBEC1BA-5000-4E85-8D58-41E3B9AC912BQ35957754-D270233A-FDA2-4FB8-AE48-2E16A47A41BDQ36067383-0FFB2716-A471-4DBD-9701-38C8E58B919AQ36202928-C060A075-E640-4309-A9F1-607B0C6A5956Q36225929-3E25BC86-EA88-4F1F-8D3B-ECB518643A88Q36357766-8C2C9AD2-919B-4C41-A48F-844EF9E1DB81Q36636671-F766D1DB-23F5-4C41-80E1-C8A949ADF93BQ36905344-7303E782-5BE1-4B71-9972-3056D5B5A323Q37137669-6BAB56E3-A356-47BF-BF07-1DFC1D8CB634Q37144539-241C57EE-B332-430E-80B8-6F2127A61563Q37397803-E3CBDB7B-1FA4-4907-BBA0-2CE6D54AC3A3Q38484497-EBBED499-F27B-4102-9F65-5B390131C0D5Q38655823-318B072E-5A35-4A78-9EDD-AED29679AF08Q38676246-B8AAA468-CD54-4C09-8DF4-3F247C549665Q38895095-138386E8-7366-4490-8B93-1788448239DAQ39500474-429936CE-BDAC-43D0-9FE7-473B330BA9B8Q43004342-3FEA4FE5-AE93-48B4-833F-1A3163B54D62Q44135736-48895174-54BA-4DF7-AC50-A73892375607Q47370738-769A2DF9-CECD-460F-8525-85A7EAB9762FQ47714470-A5B412C6-148A-4A67-9109-662480B7BEF8Q47747162-912DF3EA-3939-47B6-A046-128503532A24Q47758863-4DAD4EA3-E794-4D7D-8161-D689B71D6401
P2860
Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Decline in lung function in ly ...... se and progesterone treatment.
@en
Decline in lung function in ly ...... se and progesterone treatment.
@nl
type
label
Decline in lung function in ly ...... se and progesterone treatment.
@en
Decline in lung function in ly ...... se and progesterone treatment.
@nl
prefLabel
Decline in lung function in ly ...... se and progesterone treatment.
@en
Decline in lung function in ly ...... se and progesterone treatment.
@nl
P2860
P1476
Decline in lung function in ly ...... se and progesterone treatment.
@en
P2093
A E Tattersfield
S R Johnson
P2860
P304
P356
10.1164/AJRCCM.160.2.9901027
P407
P577
1999-08-01T00:00:00Z